Background
==========

Texel sheep, a typical \"double muscle\" breed due to a *GDF8*mutation \[[@B1]-[@B3]\], are now commercially produced throughout the world, with no adverse effects detected by objective assessments of meat quality \[[@B4]\]. However, evidence for an association between g+6723G \> A and decreased intramuscular fat and reduced eating quality has been observed \[[@B5]\]. Compared with Texel sheep, indigenous Chinese Ujumqin sheep, with no *GDF8*mutation \[[@B6]\], are less muscular and have a higher fat content, but they are superior in terms of perceived meat quality. Therefore, these two sheep breeds provide a good natural model for studying muscle and fat development, as well as for identifying myostatin genes.

Prenatal skeletal muscle development is an important determinant of both muscularity and meat quality \[[@B7]\]. In large precocial species such as sheep \[[@B8],[@B9]\] and cattle \[[@B10]\], the maximum myofiber complement of a muscle is achieved prior to birth. More than three waves of myogenic cells appear in sheep, and most myofibers form during the second half of gestation \[[@B11],[@B12]\]. However, whether the myofibers increase with a pulsed-wave mode at certain developmental stages or whether they augment evenly across developmental stages in fetal sheep remains unclear.

Myostatin, a member of the transforming growth factor-β (TGF-β) family, is predominantly expressed and secreted by skeletal muscle and functions as a negative regulator of muscle growth. Mutations in the myostatin gene lead to a hypertrophic phenotype in mice, sheep, cattle, dog, and human \[[@B1],[@B3],[@B5],[@B13]-[@B18]\]. The effect of myostatin on gene expression in prenatal muscles at the genome-wide level was recently explored in fetal cattle \[[@B19]-[@B22]\], but no studies have been conducted dynamically at multiple fetal stages comparing two pure breeds with extreme phenotypes. A recent mice study demonstrated that myoblasts from embryonic and fetal stages not only had different fusion abilities, proliferation, differentiation and responses to TGF-β, phorbol ester 12-*O*-tetradecanoylphorbol-13-acetate, and bone morphogenetic protein-4 *in vitro*, but they also differed in gene expression profiles \[[@B23]\], indicating that complicated and obvious changes in physiology and biochemistry occur during the prenatal stage *in vivo*. Therefore, investigating the subtle changes of the effect of a myostatin mutation on skeletal muscle development at multiple fetal stages using our experimental model is necessary.

Here, we examined gene expression and myofiber development in Texel and Ujumqin sheep at the transcriptome and histological levels. Our findings contribute to understanding the dynamic effects of myostatin on the biology of prenatal skeletal muscle development in large mammals. The results also provide clues into human myopathy and obesity during prenatal stages. We also identified putative candidate genes that are valuable for meat-quality traits in farm animals.

Results
=======

Histological characteristics of ovine fetal skeletal muscle development
-----------------------------------------------------------------------

We examined the number and diameter of myofibers at each developmental stage in Texel and Ujumqin sheep via histological analysis (hematoxylin and eosin \[H and E\] staining) (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Significant difference was observed in myofiber diameter between Texel and Ujumqin sheep at each development stage, except at 70 d. However, the myofiber diameter patterns of the two breeds were similar throughout the five developmental stages.

![**Changes in muscle fiber diameter throughout the five developmental stages in Texel and Ujumqin sheep**. Longissimus dorsi muscle fiber diameter was examined in cross sections using hematoxylin and eosin staining. At least three animals were used to analyze each development stage in each breed. Photomicrographs of five to eight randomly selected areas were used to calculate the diameter of myofibers in each cross section of muscle examined.](1471-2164-12-411-1){#F1}

![**Changes in muscle fiber number throughout the five developmental stages in Texel and Ujumqin sheep**. Longissimus dorsi muscle fiber number was examined in cross sections using hematoxylin and eosin staining. At least three animals were used to analyze each development stage in each breed. Photomicrographs of five to eight randomly selected areas were used to calculate the total number of myofibers in each cross section of muscle examined.](1471-2164-12-411-2){#F2}

Unexpectedly, we found that the myofiber hyperplasia profiles differed between Texel and Ujumqin fetuses (Figure [2](#F2){ref-type="fig"}). The proliferation of myofibers in Texel sheep was fastest at 70 and 85 d, particularly at 85 d, suggesting that this period is vital for muscle development in fetal Texel sheep. Myofiber hyperplasia reached a peak at 100 d in Ujumqin sheep, when the number of myofibers exceeded that of Texel sheep. Notably, with development, the number of myofibers in Texel fetuses recovered to that of Ujumqin fetuses at 120 d, although myofiber hypertrophy in Texel sheep was greater than that in Ujumqin sheep at this stage. Therefore, a new wave of myogenesis most probably occurs at 120 d in Texel sheep, given that the number of myofibers increased in Ujumqin sheep during this period.

Additionally, many small-diameter fibers occurred in the muscle at 135 d in both breeds. The small fibers could be due either to intrafascicular terminations \[[@B24]\] or have been generated by the fusion of myoblasts during the period investigated. Therefore, to explore the myogenic potential in the two breeds of sheep, we identified Pax7-positive cells in skeletal muscle at 135 d using immnofluorescence staining (IFS) and found that the ratio of the number of Pax7-positive cells (myoblasts or satellite cells) to the fibers on each muscle slide was significantly higher in the Texel fetuses than in the Ujumqin fetuses (Figure [3](#F3){ref-type="fig"}). In combination with Figure [2](#F2){ref-type="fig"}, this observation suggests that a period of 100-120 d is another new proliferative stage for myofiber hyperplasia in Texel sheep. Higher numbers of Pax7-positive cells were correlated with a higher muscle mass in Texel sheep during both the prenatal and postnatal stages.

![**Identification of Pax7-positive cells in longissimus dorsi muscle by immunofluorescence staining**. Longissimus tissue sections were stained with fluorescent antibodies Pax7 (green) and laminin (red) at 135 d of gestation, respectively. A-D are the same frozen section stained with the two different fluorescent antibodies (400×). The corresponding antigens in muscle are indicated by an arrow (Pax7) and an arrowhead (laminin).](1471-2164-12-411-3){#F3}

Microarray experiment
---------------------

A mean transcript sequence identity of 97% was found between ovine and bovine orthologs, which probably highlights the utility of the microarray technique with ovine samples \[[@B25]\]. However, some no-reporting probe sets were found, partly because of the poor performance of the probe sets with samples from a related species. The best way to resolve this type of problem is to use a species-specific microarray. In the present study, we applied the first specialized and standardized transcriptome-wide sheep oligo DNA microarray (Agilent Sheep Gene Expression Microarray; Agilent Technologies, Santa Clara, CA, USA). Due to improvements in species specificity, the average detectable rate of all probe sets reached 87.83% (Additional file [1](#S1){ref-type="supplementary-material"}), which enabled us to capture the subtle changes in gene expression.

A pool of differentially expressed (DE) probes from the two groups was used for a systematic hierarchical clustering to gain insight into the transcriptome-wide similarities among all 31 individuals investigated (Figure [4](#F4){ref-type="fig"}). We found that individuals at the same developmental stage were clustered together regardless of their genetic background, indicating that differences derived during development were larger than those from the genetic backgrounds between the breeds.

![**Hierarchical clustering between the differentially expressed genes and individuals from the two sheep breeds**. Clustering was performed using GeneSpring 10.0. A one-way analysis of variance was applied to two within-breed contrasts across developmental time. A pool of the differentially expressed probes from the two groups was used for system hierarchical clustering to clarify the transcriptome-wide similarities among all 31 individuals investigated.](1471-2164-12-411-4){#F4}

Gene expression in skeletal muscle at various developmental stages between breeds
---------------------------------------------------------------------------------

According to the primary functions of different genes including muscle, lipid, and the immune system, we visualized the data on MA and bar plots (Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). Combined with Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}, Figure [6](#F6){ref-type="fig"} also suggests the phenotypic profile in muscle and the profile of a given category of DE genes at different developmental stages. The biological functions and canonical pathways were explored at various developmental stages in Texel and Ujumqin sheep (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). The partial DE genes in the two breeds of sheep at various developmental stages are listed in Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"} (the full set of differential genes at each developmental stage between the breeds is listed in Additional files [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, [4](#S4){ref-type="supplementary-material"}, [5](#S5){ref-type="supplementary-material"} and [6](#S6){ref-type="supplementary-material"}).

![**MA plot for differential genes in Texel and Ujumqin sheep**. Genes expressed more highly in Ujumqin sheep are on the bottom, and genes expressed more highly in Texel sheep are on top. Genes involved in muscles, lipids, and the immune system are denoted by blue triangles, green circles, and red rectangles, respectively. For example, *HLA-DQB1*and *AR*were highly expressed in Texel, whereas *MYL6B*was highly expressed in Ujumqin sheep. Other genes expressed differentially are denoted by gray rectangles.](1471-2164-12-411-5){#F5}

![**Abundance of primary functional clustering of differentially expressed genes**. Counts of genes involved in muscles, lipids, and the immune system are represented by the ratio of functional categories relative to the total number of genes that exists in the microarray chip for each of those categories, respectively. The ratio illustrates the abundance of different clusters of differentially expressed genes between Texel and Ujumqin sheep at five developmental stages (70, 85, 100, 120, and 135 d of gestation).](1471-2164-12-411-6){#F6}

###### 

Summary of the differentially expressed genes between T70 and U70 using IPA

  Top Bio Functions                                                           
  ------------------------------------------------------- ------------------- ---------------
  *Cance*r^4^                                             5.82E-08-.93E-03    51
  *Cardiovascular Disease*^4^                             2.61E-06-7.93E-03   19
  Developmental Disorder                                  2.61E-06-7.93E-03   12
  Hypersensitivity Response                               8.91E-06-7.93E-03   8
  Inflammatory Response                                   1.05E-05-7.93E-03   25
  **Molecular and Cellular Functions**                                        
  **Name**                                                **p-value**         **Molecules**
  Cell-To-Cell Signaling and Interaction                  1.77E-06-7.93E-03   32
  Cellular Movement                                       8.91E-06-7.93E-03   25
  Lipid Metabolism                                        9.16E-06-7.93E-03   25
  Molecular Transport                                     9.16E-06-7.93E-03   28
  Small Molecule Biochemistry                             9.16E-06-7.93E-03   30
  **Physiological System Development and Function**                           
  **Name**                                                **p-value**         **Molecules**
  Tissue Development                                      1.77E-06-7.93E-03   24
  Hematological System Development and Function           7.13E-06-7.93E-03   22
  Hematopoiesis                                           8.91E-06-7.93E-03   9
  Immune Cell Trafficking                                 8.91E-06-7.93E-03   19
  Skeletal and Muscular System Development and Function   2.68E-05-7.93E-03   18
  **Top Canonical Pathways**                                                  
  **Name**                                                **p-value**         **Ratio^3^**
  Acute Phase Response Signaling                          2.2E-03             6/178 (0.034)
  Glycolysis/Gluconeogenesis                              7.65E-03            4/142 (0.028)
  *N*-Glycan Biosynthesis                                 9.44E-03            3/93 (0.032)
  Calcium Signaling                                       1.17E-02            5/204 (0.025)
  CXCR4 Signaling                                         3.31-02             4/169 (0.024)

1\. The p-value was calculated using a right-tailed Fisher\'s exact test. 2. The number of genes enriched in corresponding functions. 3. The ratio was calculated as the number of genes from our data set that overlap with the canonical pathway in question divided by the total number of genes represented in that canonical pathway.

4\. Italicized terms such as \"*Cancer*\" and \"*Cardiovascular Disease*\" represent a biased annotation or are not related to the aim of the study.

IPA version: 8.7 (release date: 09-17-2010)

Content version: 3202 (release date: 07-07-2010)

Reference set: Ingenuity knowledge base (genes only)

Relationships to include: direct and indirect

Includes endogenous chemicals

Filter summary: Consider all molecules and/or relationships

###### 

Summary of the differentially expressed genes between T85 and U85 using IPA

  Top Bio Functions                                                       
  --------------------------------------------------- ------------------- ---------------
  *Cancer*^4^                                         2.37E-07-1.98E-02   35
  Inflammatory Response                               3.15E-06-2.00E-02   23
  Developmental Disorder                              1.37E-05-1.94E-02   8
  Skeletal and Muscular Disorder                      5.76E-05-1.85E-02   33
  Genetic Disorder                                    5.77E-05-2.00E-02   54
  **Molecular and Cellular Functions**                                    
  **Name**                                            **p-value**         **Molecules**
  Cell-To-Cell Signaling and Interaction              3.46E-05-2.00E-02   23
  Lipid Metabolism                                    2.49E-04-2.00E-02   16
  Molecular Transport                                 2.49E-04-2.00E-02   14
  Small Molecule Biochemistry                         2.49E-04-2.00E-02   18
  *Drug Metabolism*^4^                                3.71E-04-2.00E-02   5
  **Physiological System Development and Function**                       
  **Name**                                            **p-value**         **Molecules**
  Hematological System Development and Function       3.46E-05-2.00E-02   17
  *Endocrine System Development and Function*^4^      3.71E-04-1.98E-02   5
  *Visual System Development and Function*^4^         3.71E-04-3.71E-04   2
  Hematopoiesis                                       3.72E-04-2.00E-02   8
  Immune Cell Trafficking                             3.72E-04-1.98E-02   16
  **Top Canonical Pathways**                                              
  **Name**                                            **p-value**         **Ratio^3^**
  Glycolysis/Gluconeogenesis                          1.34E-04            5/142 (0.035)
  Fructose and Mannose Metabolism                     2.19E-04            4/145 (0.028)
  Pentose Phosphate Pathway                           9.13E-04            3/89 (0.034)
  Dendritic Cell Maturation                           1.31E-03            5/188 (0.027)
  VEGF Signaling                                      9.55E-03            3/99 (0.03)

Symbols and analytical settings are the same as in Table 1.

###### 

Summary of differentially expressed genes between T100 and U100 using IPA

  Top Bio Functions                                                       
  --------------------------------------------------- ------------------- ---------------
  *Respiratory Disease*^4^                            7.71E-05-2.60E-02   3
  Metabolic Disease                                   1.05E-04-2.51E-02   8
  Hypersensitivity Response                           2.08E-04-2.51E-02   3
  Inflammatory Response                               2.08E-04-3.57E-02   11
  *Cancer*^4^                                         5.03E-04-1.92E-02   14
  **Molecular and Cellular Functions**                                    
  **Name**                                            **p-value**         **Molecules**
  Lipid Metabolism                                    2.91E-11-3.57E-02   16
  Small Molecule Biochemistry                         2.91E-11-3.57E-02   21
  Vitamin and Mineral Metabolism                      2.91E-11-2.60E-02   16
  Molecular Transport                                 8.41E-06-3.57E-02   19
  Cellular Movement                                   2.08E-04-3.57E-02   5
  **Physiological System Development and Function**                       
  **Name**                                            **p-value**         **Molecules**
  Hematological System Development and Function       2.08E-04-3.57E-02   11
  Immune Cell Trafficking                             2.08E-04-3.57E-02   9
  Lymphoid Tissue Structure and Development           2.08E-04-3.57E-02   4
  Tissue Development                                  4.79E-04-3.57E-02   9
  Hematopoiesis                                       6.96E-04-3.57E-02   6
  **Top Canonical Pathways**                                              
  **Name**                                            **p-value**         **Ratio^3^**
  T-Helper Cell Differentiation                       2E-03               3/72 (0.042)
  Inositol Metabolism                                 3.73E-03            3/97 (0.031)
  Biosynthesis of Steroids                            5.98E-03            2/128 (0.016)
  EIF2 Signaling                                      3.89E-02            2/103(0.019)
  VEGF Signaling                                      3.98E-02            2/99 (0.02)

Symbols and analytical settings are the same as in Table 1.

###### 

Summary of differentially expressed genes between T120 and U120 using IPA

  Top Bio Functions                                                                      
  ------------------------------------------------------------------ ------------------- ---------------
  Hypersensitivity Response                                          9.54E-06-1.19E-02   7
  Inflammatory Response                                              9.54E-06-1.19E-02   18
  *Cancer*^4^                                                        3.78E-05-1.19E-02   41
  Hematological Disease                                              5.66E-05-1.19E-02   7
  Immunological Disease                                              5.66E-05-1.19E-02   7
  **Molecular and Cellular Functions**                                                   
  **Name**                                                           **p-value**         **Molecules**
  Cell-To-Cell Signaling and Interaction                             9.54E-06-1.19E-02   17
  Lipid Metabolism                                                   1.16E-05-1.19E-02   16
  Small Molecule Biochemistry                                        1.16E-05-1.19E-02   20
  Carbohydrate Metabolism                                            3.54E-05-1.19E-02   5
  *Drug Metabolism*^4^                                               3.54E-05-1.19E-02   10
  **Physiological System Development and Function**                                      
  **Name**                                                           **p-value**         **Molecules**
  Hematological System Development and Function                      9.54E-06-1.19E-02   23
  Immune Cell Trafficking                                            9.54E-06-1.19E-02   13
  Nervous System Development and Function                            1.69E-05-1.19E-02   8
  Tissue Development                                                 1.69E-05-1.19E-02   13
  *Reproductive System Development and Function*^4^                  7.17E-05-1.19E-02   10
  **Top Canonical Pathways**                                                             
  **Name**                                                           **p-value**         **Ratio^3^**
  *Altered T Cell and B Cell Signaling in Rheumatoid Arthritis*^4^   1.54E-04            5/91 (0.055)
  NF-kB Signaling                                                    1.87E-03            5/155 (0.032)
  Autoimmune Thyroid Disease Signaling                               2.77E-03            3/61 (0.049)
  *Atherosclerosis Signaling*^4^                                     2.92E-03            4/113 (0.035)
  Taurine and Hypotaurine Metabolism                                 3.53E-03            2/47 (0.043)

Symbols and analytical settings are the same as in Table 1.

###### 

Summary of differentially expressed genes between T135 and U135 using IPA

  Top Bio Functions                                                       
  --------------------------------------------------- ------------------- ---------------
  *Cancer*^4^                                         9.23E-06-2.87E-02   7
  *Reproductive System Disease*^4^                    9.23E-06-6.44E-03   7
  Genetic Disorder                                    3.22E-03-2.87E-02   5
  Immunological Disease                               3.22E-03-3.22E-03   1
  Infection Mechanism                                 3.22E-03-4.11E-02   4
  **Molecular and Cellular Functions**                                    
  **Name**                                            **p-value**         **Molecules**
  Cell Cycle                                          5.50E-04-2.87E-02   3
  Cell Death                                          1.04E-03-2.43E-02   8
  Cell-To-Cell Signaling and Interaction              3.22E-03-4.42E-02   5
  Cellular Assembly and Organization                  3.22E-03-4.42E-02   7
  Cellular Compromise                                 3.22E-03-4.42E-02   3
  **Physiological System Development and Function**                       
  **Name**                                            **p-value**         **Molecules**
  Embryonic Development                               5.50E-04-2.55E-02   5
  Tissue Development                                  5.50E-04-4.11E-02   7
  Hematological System Development and Function       2.47E-03-4.42E-02   7
  Cell-mediated Immune Response                       3.22E-03-4.42E-02   2
  Nervous System Development and Function             3.22E-03-6.44E-03   2
  **Top Canonical Pathways**                                              
  **Name**                                            **p-value**         **Ratio^3^**
  LPS/IL-1-mediated Inhibition of RXR Function        3.61E-03            4/216 (0.019)
  Histidine Metabolism                                1.26E-02            2/120 (0.017)
  PXR/RXR Activation                                  2.2E-02             2/91 (0.022)
  Arginine and Proline Metabolism                     2.68E-02            2/183 (0.011)
  Glycerolipid Metabolism                             4.51E-02            2/156 (0.013)

Symbols and analytical settings are the same as in Table 1.

###### 

Examples of downregulated genes between Texel and Ujumqin sheep at the same developmental stage

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Probe Name     Genbank Accession Number       Gene                                                                                                   Fold\    Developmental\
                                                                                                                                                       Change   stage
  -------------- ------------------------------ ------------------------------------------------------------------------------------------------------ -------- ----------------
  A_70_P069356   [EE752033](EE752033)           *Homo sapiens*selenoprotein I (SELI)                                                                   15.35    70 d

  A_70_P016291   [EE793140](EE793140)           *Homo sapiens*Rho-related BTB domain containing 3 (RHOBTB3)                                            5.16     70 d

  A_70_P006561   [EE781286](EE781286)           *Homo sapiens*nucleolar protein 7 (NOL7)                                                               4.54     70 d

  A_70_P004621   [EE863207](EE863207)           *Homo sapiens*signal transducer and activator of transcription 3 (STAT3)                               2.38     70 d

  A_70_P001706   [FE033261](FE033261)           *Homo sapiens*aldolase A, fructose-bisphosphate, transcript variant 1 (ALDOA)                          2.28     70 d

  A_70_P056812   [NM_001009763](NM_001009763)   *Homo sapiens*leptin receptor (LEPR)                                                                   2.24     70 d

  A_70_P005526   [CO202686](CO202686)           *Homo sapiens*stathmin-like 2 (STMN2)                                                                  8.23     85 d

  A_70_P016291   [EE793140](EE793140)           *Homo sapiens*Rho-related BTB domain containing 3 (RHOBTB3)                                            5.99     85 d

  A_70_P068196   [EE779349](EE779349)           *Homo sapiens*trefoil factor 3 (TFF3)                                                                  5.19     85 d

  A_70_P039551   [NM_001009266](NM_001009266)   *Homo sapiens*proopiomelanocortin (POMC)                                                               5.00     85 d

  A_70_P037096   [EE773353](EE773353)           *Homo sapiens*phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PIK3R1), transcript variant 2   2.77     85 d

  A_70_P001731   [EE780294](EE780294)           *Homo sapiens*trafficking protein, kinesin-binding 1 (TRAK1)                                           8.04     100 d

  A_70_P017916   [EE828626](EE828626)           *Homo sapiens*S100 calcium-binding protein A11(S100A11)                                                8.03     100 d

  A_70_P032741   [CF116713](CF116713)           *Bos taurus*defensin, beta (DEFB)                                                                      7.09     100 d

  A_70_P001411   [EE873259](EE873259)           *Bos taurus*secretoglobin, family 1D, member 2 (SCGB1D2)                                               5.59     100 d

  A_70_P039326   [NM_001009410](NM_001009410)   *Homo sapiens*thyroid-stimulating hormone receptor (TSHR)                                              4.50     100 d

  A_70_P045271   [EE788300](EE788300)           *Homo sapiens*paraoxonase 1 (PON1)                                                                     4.01     100 d

  A_70_P068131   [DQ152973](DQ152973)           *Homo sapiens*lymphoid enhancer-binding factor1 (LEF-1)                                                2.23     100 d

  A_70_P035741   [FE033512](FE033512)           *Bos taurus*X (inactive)-specific transcript (XIST), noncoding RNA                                     65.59    120 d

  A_70_P005526   [CO202686](CO202686)           *Homo sapiens*stathmin-like 2 (STMN2)                                                                  21.27    120 d

  A_70_P018856   [EE791277](EE791277)           *Homo sapiens*ATP-binding cassette, subfamily B (MDR/TAP), member 4 (ABCB4)                            15.37    120 d

  A_70_P024811   [EE777383](EE777383)           *Homo sapiens*epithelial cell adhesion molecule (EPCAM)                                                7.16     120 d

  A_70_P019481   [EE828813](EE828813)           *Homo sapiens*transformation/transcription domain-associated protein (TRRAP)                           4.92     120 d

  A_70_P030147   [NM_001009261](NM_001009261)   *Homo sapiens*prion protein 2 (doublet) (PRND)                                                         4.84     120 d

  A_70_P025536   [FE022583](FE022583)           *Homo sapiens*glutamate receptor, metabotropic 8 (GRM8)                                                4.62     120 d

  A_70_P051317   [NM_001009479](NM_001009479)   *Homo sapiens*natriuretic peptide precursor C (NPPC)                                                   4.46     120 d

  A_70_P030402   [NM_001093787](NM_001093787)   *Homo sapiens*kallikrein 1 human (KLK1)                                                                4.37     120 d

  A_70_P051037   [NM_001009451](NM_001009451)   *Homo sapiens*solute carrier family 2 (facilitated glucose/fructose transporter), member 5 (SLC2A5)    8.14     135 d

  A_70_P035536   [DY520412](DY520412)           *Homo sapiens*ankyrin repeat domain 1 (cardiac muscle) (ANKRD1)                                        5.37     135 d

  A_70_P016291   [EE793140](EE793140)           *Homo sapiens*Rho-related BTB domain containing 3 (RHOBTB3)                                            4.14     135 d
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Differentially expressed probes were detected from five *t*-test analyses using GeneSpring 10.0 (Agilent Technologies).

1\. Original probe name in microarray analysis. 2. GenBank Accession Number of expressed sequence tags provided by the manufacturer according to the specific probe name. 3. The highly homologous human sequences acquired using BLASTN search in NCBI (search setting: query coverage not less than 50%, E-value less than 1.00E-100).

###### 

Examples of upregulated genes between Texel and Ujumqin sheep at the same developmental stage

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Probe Name^1^   GenBank^2^Accession Number     Gene^3^                                                                                                 Fold\     Developmental\
                                                                                                                                                         Change    Stage
  --------------- ------------------------------ ------------------------------------------------------------------------------------------------------- --------- ----------------
  A_70_P046666    [EE795873](EE795873)           *Homo sapiens*eukaryotic translation elongation factor 1 alpha 2 (EEF1A2)                               8.92      70 d

  A_70_P011966    [FE031658](FE031658)           *Homo sapiens*transmembrane channel-like protein 5 (TMC5)                                               6.74      70 d

  A_70_P019721    [EE787688](EE787688)           *Homo sapiens*complement component 4-binding protein, alpha (C4BPA)                                     6.64      70 d

  A_70_P024986    [EE825499](EE825499)           *Homo sapiens*CD8a molecule, complete cds (CD8A)                                                        6.06      70 d

  A_70_P003451    [CU652121](CU652121)           *Homo sapiens*cardiomyopathy-associated 5 (CMYA5)                                                       4.09      70 d

  A_70_P046666    [EE795873](EE795873)           *Homo sapiens*eukaryotic translation elongation factor 1 alpha 2 (EEF1A2)                               16.21     85 d

  A_70_P063416    [EE775784](EE775784)           *Homo sapiens*fructose-1,6-bisphosphatase 2 (FBP2)                                                      10.39     85 d

  A_70_P037371    [EE776937](EE776937)           *Homo sapiens*actinin, alpha 3 (ACTN3)                                                                  7.83      85 d

  A_70_P054756    [EE791183](EE791183)           *Homo sapiens*apolipoprotein C-II (APOC2)                                                               6.29      85 d

  A_70_P055056    [EE768552](EE768552)           *Homo sapiens*proteoglycan 3 (PRG3)                                                                     6.03      85 d

  A_70_P050846    [CU651713](CU651713)           *Homo sapiens*myosin, heavy chain 1, skeletal muscle, adult (MYH1)                                      5.60      85 d

  A_70_P019721    [EE787688](EE787688)           *Homo sapiens*complement component 4-binding protein, alpha (C4BPA)                                     4.00      85 d

  A_70_P017031    [L08792](L08792)               *Homo sapiens*major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1)                          131.77    100 d

  A_70_P044801    [EE862627](EE862627)           *Homo sapiens*chemokine ligand 26-like protein (CCL26)                                                  10.16     100 d

  A_70_P024246    [EE859238](EE859238)           *Homo sapiens*pyruvate dehydrogenase kinase, isozyme 4 (PDK4)                                           5.85      100 d

  A_70_P057421    [EE784201](EE784201)           *Homo sapiens*MAK16 homolog (*S. cerevisiae*) (MAK16)                                                   5.22      100 d

  A_70_P070736    [EE824836](EE824836)           *Homo sapiens*thioredoxin reductase mRNA (TXNRD1)                                                       5.20      100 d

  A_70_P011371    [EE813532](EE813532)           *Homo sapiens*isopentenyl-diphosphate delta isomerase 1 (IDI1)                                          4.25      100 d

  A_70_P017031    [L08792](L08792)               *Homo sapiens*major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1)                          1389.16   120 d

  A_70_P066011    [FE028749](FE028749)           *Homo sapiens*ubiquitin-specific peptidase 9, Y-linked (USP9Y)                                          670.44    120 d

  A_70_P066386    [EE851120](EE851120)           *Homo sapiens*guanylate-binding protein 2, interferon-inducible (GBP2)                                  76.81     120 d

  A_70_P052621    [EE778111](EE778111)           *Homo sapiens*pyrophosphatase (inorganic) 1 (PPA1)                                                      14.06     120 d

  A_70_P065251    [EE748701](EE748701)           *Homo sapiens*CD48 molecule (CD48)                                                                      9.68      120 d

  A_70_P044801    [EE862627](EE862627)           *Homo sapiens*chemokine ligand 26-like protein (CCL26)                                                  7.26      120 d

  A_70_P035891    [EE805356](EE805356)           *Homo sapiens*sorting nexin 10 (SNX10)                                                                  5.93      120 d

  A_70_P000126    [EE807554](EE807554)           *Homo sapiens*guanylate-binding protein 4 (GBP4)                                                        4.97      120 d

  A_70_P016471    [EE829459](EE829459)           *Homo sapiens N*-myc upstream-regulated 1 (NDRG1)                                                       4.40      120 d

  A_70_P039346    [NM_001009789](NM_001009789)   *Homo sapiens*prostaglandin F receptor (FP) (PTGFR)                                                     4.32      120 d

  A_70_P011531    [EE776172](EE776172)           *Homo sapiens*CCAAT/enhancer-binding protein (C/EBP), beta (CEBPB)                                      4.14      120 d

  A_70_P045436    [EE827672](EE827672)           *Homo sapiens*glutathione *S*-transferase theta 1 (GSTT1)                                               4.13      120 d

  A_70_P025036    [EE746884](EE746884)           *Homo sapiens*regulator of G-protein signaling 1 (RGS1)                                                 11.22     135 d

  A_70_P049266    [EE815004](EE815004)           *Bos taurus*mRNA for T-cell receptor alpha chain, leader sequence, variable and joining region (TRA2)   7.06      135 d

  A_70_P030156    [NM_001009735](NM_001009735)   *Homo sapiens*ISG15 ubiquitin-like modifier (ISG15)                                                     4.28      135 d

  A_70_P030132    [NM_001104930](NM_001104930)   *Homo sapiens*receptor (chemosensory) transporter protein 4 (RTP4)                                      4.20      135 d

  A_70_P001016    [FE027322](FE027322)           *Homo sapiens*eukaryotic translation initiation factor 2, subunit 2 beta (EIF2S2)                       3.52      135 d
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Differentially expressed probes were detected from five *t*-test analyses using GeneSpring 10.0 (Agilent Technologies).

1\. Original probe name in the microarray analysis. 2. The GenBank Accession Number of expressed sequence tags provided by the manufacturer according to the specific probe name. 3. The highly homologous human sequences acquired by a BLASTN search in NCBI (search setting: query coverage not less than 50%, E-value less than 1.00E-100).

### T70 vs. U70

The rapid increase in total muscle fiber number in the ovine fetus begins at 70 d \[[@B11],[@B12]\]. We found that the number of DE genes was highest at this stage compared with other stages: 207 probe sets, including 155 known genes and 50 expressed sequence tags (ESTs) were differentially expressed in the T70 and U70 samples. Compared with U70, 82 genes were upregulated and 73 genes were downregulated in T70. A gene ontology analysis by DAVID revealed that these upregulated genes encoded cell activation, negative regulation of apoptosis, positive regulation of peptidyl-tyrosine phosphorylation, and vesicle-mediated transport. Genes that were downregulated encoded hexose catabolism, monosaccharide catabolism, postembryonic development, alcohol catabolism, and lipid biosynthesis.

To ascertain whether some molecular events or cascades were associated with the process of skeletal muscle development, we identified four canonical pathways by DAVID and the IPA platforms, which are involved in myogenesis and muscle metabolism, including the glycolysis/gluconeogenesis pathway, *N*-glycan biosynthesis, calcium signaling, and chemokine (C-X-C motif) receptor 4 (CXCR4) signaling).

We also revealed through IPA software that genes associated with the skeletal and muscular system development and function, as well as lipid metabolism, were top biological functions (Table [1](#T1){ref-type="table"}).

We further analyzed some transcripts and found that eukaryotic translation elongation factor 1 alpha 2 (*EEF1A2*) was highly expressed in T70. In contrast, the expression levels of signal transducer and activator of transcription 3 (*STAT3*), aldolase A (*ALDOA*), and the leptin receptor (*LEPR*) were upregulated in U70.

### T85 vs. U85

In total, 115 probe sets were differentially expressed in T85 and U85, including 97 annotated genes and 18 ESTs. In contrast to U85, 50 genes were upregulated and 47 were downregulated in T85. Of these genes, immune response, cellular carbohydrate catabolism, and fatty acid metabolism were significantly overrepresented in the upregulated genes, whereas cell migration regulation was significantly overrepresented in the downregulated genes.

For all DE genes between U85 and T85, we identified four canonical pathways that were overrepresented between the two breeds: glycolysis/gluconeogenesis, fructose and mannose metabolism, the pentose phosphate pathway, and vascular endothelial growth factor (VEGF) signaling. Moreover, hematological system development and function and lipid metabolism were still significantly represented as top biofunctions. In particular, we found a cluster of genes enriched in the biofunction of skeletal and muscular disorders, suggesting a difference in skeletal muscle development between Texel and Ujumqin fetal sheep (Table [2](#T2){ref-type="table"}).

Among the DE genes, eukaryotic translation elongation factor 1 alpha 2 (*EEF1A2*), fructose-1,6-bisphosphatase 2 (*FBP2*), actinin alpha 3, proteoglycan 3 (*PRG3*), myosin heavy chain 1 (*MYH1*) were more highly expressed in Texel than in Ujumqin sheep. However, the stathmin-like 2 (*STMN2*) and phosphoinositide-3-kinase, regulatory subunit 1 alpha (*PIK3R1*) were more highly expressed in U85.

### T100 vs. U100

At this fetal developmental stage, the difference in muscle development, particularly the rate of myofiber proliferation, was most significant between the breeds. Ninety probe sets, including 70 annotated genes and 20 ESTs, were differentially expressed in T100 and U100. Among these genes, 33 were upregulated and 37 were downregulated in T100. The upregulated genes were involved in DNA binding, RNA binding, and ribonucleoproteins, whereas those that were downregulated were mostly related to steroid biosynthesis, lipid metabolism, and skeletal muscle fiber development.

For all DE genes at 100 d, hematological system development and function remained the most overrepresented physiological system, and lipid metabolism was also more active at this stage. Inositol metabolism, steroid biosynthesis, eukaryotic initiation factor 2 (EIF2) signaling, and VEGF signaling were overrepresented between T100 and U100 (Table [3](#T3){ref-type="table"}).

Within the DE genes, thyroid stimulating hormone receptor (*TSHR*) and paraoxonase 1 (*PON1*) were more highly expressed in Ujumqin sheep than in Texel sheep, whereas *OVAR-DQB1*(sheep MHC class II), pyruvate dehydrogenase kinase, isozyme 4 (*PDK4*), and thioredoxin reductase (*TXNRD1*) were upregulated in T100.

### T120 vs. U120

The discrepancy in fetal muscle development was more significant between Texel and Ujumqin sheep at 120 d. In total, 151 probe sets, including 120 annotated genes and 31 ESTs, were differentially expressed in T120 and U120. Of these genes, 63 were upregulated in T120 and 57 were upregulated in U120. The upregulated genes were specific to the immune response, leukocyte activation, and the I-kappaB kinase/NF-kappaB cascade, whereas the downregulated genes were significantly associated with the response to ethanol, the enzyme-linked receptor protein signaling pathway, and histone H2A acetylation.

Hematological system development and function, immune cell trafficking, and nervous system development and function were most overrepresented in physiological systems development and function. Furthermore, lipid metabolism was also the most overrepresented molecular and cellular function. Several canonical pathways were associated with immune and lipid metabolism disorders, such as nuclear factor (NF)-kB signaling and atherosclerosis signaling (Table [4](#T4){ref-type="table"}).

Among DE genes between T120 and U120, *OVAR-DQB1*(sheep MHC class II), guanylate-binding protein 2; interferon-inducible, guanylate-binding protein 4; and CCAAT/enhancer-binding protein (C/EBP) beta (*CEBPB*) were upregulated in T120. Both *STMN2*and transformation/transcription domain-associated protein (*TRRAP*) were upregulated in U120.

### T135 vs. U135

Seventy-two probe sets, including 58 annotated genes and 14 ESTs, were differentially expressed in T135 and U135. Of these genes, 27 were upregulated in T135 and another 31 were more highly expressed in U135. The immune response process was overrepresented in the upregulated genes, and mitosis was represented significantly in the downregulated genes.

For the pool of DE genes, embryonic development and tissue development, hematological system development and function, cell-mediated immune response, and nervous system development and function were listed at the top of physiological system development and function. Cellular functions such as the cell cycle, cell death, and cell-to-cell signaling and interaction were more active. Notably, a pathway involved in glycerolipid metabolism was identified between T135 and U135 (Table [5](#T5){ref-type="table"}), two members of which (*ALDH1A1*and *APOC2*) were upregulated in U135.

In terms of physiological system development and functions, differences in the immune and hematological systems were most significant between Texlel and Ujumqin sheep during muscle development. Then, differences in nervous system development and function became more prominent at later gestational stages. The most obvious differences in molecular and cellular functions were lipid metabolism and cell communication between the two breeds. Several overrepresented canonical pathways related to muscle and adipose development (Table [5](#T5){ref-type="table"}), which were particularly noteworthy, underpinned the differences in skeletal muscle and adipose tissue between the two breeds at the fetal stage.

Quantitative PCR validation of microarray gene expression
---------------------------------------------------------

To confirm the differential expression of the genes in the microarray analysis, we selected 15 genes to validate by quantitative PCR (qPCR). Among these, eight genes (*ACTB, TNC, MYO9A, MYL6B, MYH1, CASQ1, TPM2*, and *TMOD4*) encode myofibrillar proteins and two (*EEF1A2*and *LEF-1*) are transcription factors that regulate the genes associated with myogenesis. *PIK3R1*is involved in fat metabolism regulation, whereas *TRRAP, TXNRD1*, and *INSIG1*participate in the regulation of gene expression and cell proliferation. Additionally, we also detected *MSTN*expression during skeletal muscle development. As in previous studies \[[@B26]-[@B29]\], *RpLP0*was chosen as an ideal reference gene to normalize the data. The ratios of 12 DE genes at particular developmental stages in the two sheep breeds in the microarray analysis agreed with the qPCR results (Table [8](#T8){ref-type="table"}).

###### 

Validation of differential expression by quantitative PCR (qPCR)

                          Ratio of gene expression between two sheep breeds^1^                               
  ---------- ------------ ------------------------------------------------------ --------- -------- -------- -------
  *EEF1A2*   qPCR         0.23                                                   1.36      4.17     0.57     0.11
             microarray   8.92                                                   16.21\*   1.78     0.78     0.98
  *TXNRD1*   qPCR         131.73                                                 382.54    35.06    2.3      1.16
             microarray   1.38                                                   1.14      5.20\*   3.15     0.94
  *INSIG1*   qPCR         0.82                                                   1.65      0.32     0.16     0.10
             microarray   1.10                                                   1.11      0.34\*   0.88     0.87
  *LEF-1*    qPCR         6.64                                                   21.65     0.51     0.78     0.16
             microarray   0.52                                                   0.59      0.47\*   0.50     0.57
  *TMOD4*    qPCR         81.5                                                   714.32    323.03   3.7      0.02
             microarray   2.80\*                                                 3.52\*    1.54     1.15     0.80
  *TPM2*     qPCR         0.29                                                   0.87      1.48     0.17     0.84
             microarray   0.48\*                                                 0.60      1.54     3.03     1.10
  *MYO9A*    qPCR         0.14                                                   0.15      0.25     0.31     0.12
             microarray   0.49\*                                                 0.61      1.02     0.75     1.20
  *TRRAP*    qPCR         0.06                                                   0.30      0.85     1.11     0.42
             microarray   0.51                                                   0.35      1.79     0.20\*   0.26
  *TNC*      qPCR         0.21                                                   0.54      5.12     6.23     10.46
             microarray   0.88                                                   0.69      0.41\*   0.62     1.78
  *PIK3R1*   qPCR         0.61                                                   0.44      0.23     1.06     0.29
             microarray   0.51                                                   0.36\*    1.03     1.92     1.14
  *ACTB*     qPCR         1.79                                                   0.16      0.73     0.35     0.85
             microarray   1.09                                                   0.55      0.48\*   1.39     0.47
  *MYL6B*    qPCR         0.35                                                   1.0       3.44     0.84     0.85
             microarray   0.42\*                                                 1.14      0.88     1.16     1.04
  *MYH1*     qPCR         0.84                                                   1.36      0.21     0.57     0.56
             microarray   1.89                                                   5.60\*    1.56     1.19     1.09
  *CASQ1*    qPCR         0.51                                                   0.76      0.56     0.07     2.79
             microarray   2.16 \*                                                2.31      1.23     0.82     0.72
  *MSTN*     qPCR         0.81                                                   0.71      0.54     0.47     0.61
             microarray   0.69                                                   0.92      0.62     0.56     0.81

1\. The data in the rows are the ratio of the 2^ΔΔCT^values for the qPCR in a Texel sheep sample relative to that in the Ujumqin sheep sample at the same developmental stage. The microarray row provides gene expression ratios in Texel sheep samples divided by those in Ujumqin sheep samples at the same developmental stage. \*Differentially expressed genes in the microarray analysis with a statistically significant difference at p \< 0.05.

Discussion
==========

Characteristics of prenatal muscle fiber development in sheep
-------------------------------------------------------------

Wilson *et al.*and Maier *et al.*showed that at least three waves of myogenesis occurred until d 76 of gestation in sheep \[[@B9],[@B11]\]. We demonstrated that the myofiber numbers increase sharply with a pulsed-wave mode at a particular developmental stage in sheep. This is the first time that the mode of fetal myofiber proliferation was revealed in a large mammal during the second half of gestation. In addition to the longissimus dorsi muscle, similar patterns of myofiber proliferation were found in the semitendenosus, gluteus medius, gastrocnemius, and triceps brachii muscles in Texel and Ujumqin fetal sheep (data not shown). These findings indicate that the specific developmental stage during which myogenic surges of myofiber hyperplasia appeared is pivotal for fetal muscle development as well as postnatal muscularity potential in sheep.

Unlike the studies of Wilson *et al.*and Maier *et al.*, who identified different generations of myogenic cells using electron microscopy \[[@B9],[@B11]\], we counted the muscle fibers under a light microscope and found many small-diameter fibers until 135 d in both breeds. We considered that at least part of the small fibers must have been generated by the fusion of myoblasts (or satellite cells) during the study period. Pax7 plays an important role conferring myogenic potential to these progenitor cells \[[@B30]\], and Pax7 is an ideal cell marker of myogenic progenitor cells such as myoblasts and satellite cells \[[@B31]\]. Our findings indicate a higher potential for postnatal muscle growth that entails more Pax7-positive cells in the fetal stage.

Gene expression in the two breeds at various developmental stages
-----------------------------------------------------------------

Of the five prenatal stages, the numbers of DE genes in the two sheep breeds were highest at 70 and 120 d, indicating that rapid myofiber proliferation included numerous genes during the myogenic process. However, two surges of myofiber proliferation appeared at 85 and 120 d in Texel fetuses, probably because the expression of more genes associated with myoblast proliferation and differentiation at 70 d prepared for the myofiber hyperplasia that followed at 85 d, and more genes related to the immune system were differentially expressed between T70 and U70 (Figure [6](#F6){ref-type="fig"}), which led to larger total counts of DE genes. The difference between the two sheep breeds in the timing of myogenesis in terms of transcriptomic levels was similar to that found between pig breeds \[[@B32]\]. Cagnazzo *et al.*showed that myogenesis-related gene expression is greater in early Duroc (a breed with more intramuscular fat) embryos than in early Pietrain (a highly muscled breed) embryos at 14-49 d of gestation, whereas the opposite was found in late embryos (63-91 d of gestation) \[[@B32]\]. The present findings suggest that highly muscled breeds have a longer myogenic process during prenatal stages and that myogenesis is more intense in late-stage fetuses, which was validated by Pax7-cell staining in longissimus muscle cross sections (Figure [3](#F3){ref-type="fig"}). However, whether this myogenic process is the same in sheep as in pigs at earlier embryonic stages remains to be investigated.

We found that the immune and hematological systems\' development and function were most overrepresented of all physiological systems and functions, accompanied by muscle system development, which was consistent with a microarray developmental analysis in cattle fetuses \[[@B21]\]. Recent discoveries have revealed complex interactions between skeletal muscle and the immune system that regulate muscle regeneration and myogenesis, and many immune molecules, such as tumor necrosis factor-alpha (TNF-α), NF-kB, interleukin (IL)-4, IL-6, IL-10, and leukemia inhibitory factor are involved in muscle cell proliferation and differentiation \[[@B33]-[@B38]\]. In most cases, whether perturbation in the same signaling pathways related to myogenesis occurs will determine normal myogenic development or muscle disorders. Therefore, the pathways associated with immune and muscle disorders in this work are valuable for human myopathy at the prenatal stage. The hematological system is also implicated in myogenesis \[[@B39]-[@B43]\], which probably reflects the systemic requirement for muscle function during fetal development.

Nervous system development was overrepresented in the last two development stages in the two sheep breeds. Neurons are indispensable for maintaining normal muscle physiological function and also parallel the skeletal muscle in auxology. Comprehensive and close interactions occur between muscles and the nervous system during development \[[@B44]-[@B46]\]. Muscle development is regulated by the central nervous system in *Drosophila*and pigs \[[@B47],[@B48]\], and muscle fiber type is dependent on the pattern of innervation of a muscle established due to differential projection patterns between fast and slow motoneurons \[[@B49],[@B50]\]. Animals with different muscle phenotypes undergo diverse innervation patterns during fetal development. Double-muscled cattle have an additional 13-26% increased branching in terminal axons compared to that in normal cattle caused by a real increase in the number of myofibers \[[@B51]\].

We identified several valuable canonical pathways directly associated with muscle development and function, myogenesis, myoblast proliferation, and the cell cycle in muscle at various developmental stages, such as calcium \[[@B52]\], CXCR4 \[[@B53]-[@B55]\], and VEGF signaling \[[@B56]\]. Furthermore, other pathways involved in adipose and muscle metabolism, such as inositol metabolism, steroid biosynthesis, EIF2 signaling, glycerolipid metabolism, the glycolysis/gluconeogenesis pathway, and *N*-glycan biosynthesis, are significantly affected during development. Steelman *et al.*suggested that Wnt signaling is a potential downstream target of myostatin for postnatal skeletal muscle growth and hypertrophy in mice \[[@B57]\]. However, we focused on the transcriptome during prenatal stages rather than postnatal stages and found that various canonical pathways are predominant in skeletal muscle development at different stages due to a myostatin mutation in sheep.

DE genes involved in muscle and adipose development
---------------------------------------------------

*STAT3*, a member of the *STAT*family and a cooperator in the Janus kinase pathway, plays a dual role in the regulation of myoblast proliferation and differentiation, but is dependent on interactions with various cofactors \[[@B58]-[@B62]\]. We found that *STAT3*expression was higher in U70 than T70, which suggests that *STAT3*is most probably associated with the differentiation rather than proliferation of myoblasts. The GO analysis of DE genes between T70 and U70 confirmed our presumption, and muscle fiber hyperplasia was more intense in T70 (Figure [2](#F2){ref-type="fig"}) as well.

*ALDOA*is responsible for significant activation during the differentiation of chicken primary myoblasts and plays an important role in muscle gene transcription \[[@B63],[@B64]\]. In our study, a higher *ALDOA*expression level in U70 indicated that more myoblasts exited the cell cycle and entered differentiation in U70 than those in T70. The leptin receptor (LEPR), a protein secreted from adipocytes, is responsible for fat mass regulation via leptin in the hypothalamus \[[@B65],[@B66]\]. *LEPR*expression was higher in U70 than in T70. Whether the higher *LEPR*expression at prenatal stages is associated with high postnatal adipose deposition remains to be investigated.

Both hyperplasia and hypertrophy continued in skeletal muscle at 85 d. *FBP2*, which encodes a gluconeogenesis regulatory enzyme that catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate and inorganic phosphate, was expressed higher in T85 than in U85. A previous study suggested that FBPase participates in some nuclear processes during the development and regeneration of skeletal muscle \[[@B67],[@B68]\]. Additionally, *PRG3*expression was also higher in T85. Previous studies have shown that *PRG3*plays a role in some early aspects of skeletal myogenesis \[[@B69]-[@B72]\].

The expression levels of *PIK3R1, TSHR*, and *PON1*were higher in U85 and U100 than that in T85 or T100. Previous studies have demonstrated that these genes are involved in fat metabolism and adipocyte development \[[@B73]-[@B76]\].

PDK4, a gene that was upregulated in T100, is a key regulatory enzyme involved in switching the energy source from glucose to fatty acids in response to physiological conditions. The pyruvate dehydrogenase complex occupies a central and strategic position in muscle intermediary metabolism and is primarily regulated by phosphorylation/dephosphorylation \[[@B77]\]. In addition, *PDK4*is significantly associated with intramuscular fat and muscle water content \[[@B78]\], indicating that *PDK4*is involved in meat quality.

TXNRD1 is a variant of thioredoxin reductase, an important selenoprotein that maintains cellular redox balance and regulates several redox-dependent processes during apoptosis, cell proliferation, and differentiation \[[@B79]-[@B81]\]. LEF1 is a transcription factor involved in the regulation of myogenesis. Loss of Lef1-mediated repression results in an increased number of cells expressing Pax-7 and Pax-3, suggesting that Wnt signaling via Lef1 acts to regulate the number of premyogenic cells in somites \[[@B82]\]. In our study, *LEF1*expression was higher in U100 than that in T100, which is consistent with the rapid proliferation of myofibers in U100. Although transcription factor activity is predominantly manifested at the protein level, the difference in *LEF1*expression level indicated a potential difference of LEF1 between breeds.

*OVAR-DQB1*(sheep MHC class II) was expressed much higher in T100 and T120, particularly in T120 (Table [7](#T7){ref-type="table"}), compared with U 100 and U120. Results from Karpati *et al.*indicated that the class I molecule may be involved in the fusion of myogenic cells during muscle regeneration \[[@B83]\]. Honda and Rostami demonstrated that the expression of class I antigens on muscle cells is not only immunologically modulated but also developmentally regulated, and that these antigens may play a role in cell recognition and interaction during the myogenic fusion process. The presence of the antigens, however, was transitory, and they disappeared as myoblasts fused and differentiated into multinucleate myotubes \[[@B84]\].

CEBPB, an important transcription factor, acts as a indispensable regulator of adipocyte differentiation during adipogenesis \[[@B85]-[@B87]\]. We found that *CEBPB*expression was higher in skeletal muscle in T120 than in U120, indicating a key difference in adipogenesis between Texel and Ujumqin sheep. However, which breeds contain more adipose mass than the other at this developmental stage remains to be investigated.

*TRRAP*, which was downregulated in T120, in contrast to that in U120, is vital for embryonic survival and control of the mitotic checkpoint \[[@B88]-[@B91]\]. Deletion of *TRRAP*leads to a reduced level of beta-catenin ubiquitination, a lower degradation rate, and accumulation of the beta-catenin protein, whereas *TRRAP*knockdown results in abnormal retention of beta-catenin at chromatin and concomitant hyperactivation of the canonical Wnt pathway \[[@B92]\]. However, the canonical Wnt pathway is downregulated in the absence of myostatin through beta-catenin, whereas the Wnt/calcium pathway is upregulated \[[@B57]\], suggesting that *TRRAP*may negatively regulate skeletal muscle development between the canonical Wnt and the Wnt/calcium pathways through beta-catenin at 120 d. Further efforts are warranted to test the effect of *TRRAP*on skeletal muscle development.

Other than the genes discussed above, we found that *MSTN*expression was lower in Texel than in Ujumqin sheep through the five development stages (Table [8](#T8){ref-type="table"}). This result indicated that *MSTN*downregulation contributed to the hyperplasia and hypertrophy of myofibers in Texel sheep through the second half of gestation. Moreover, the genes discussed above are potential myostatin targets for further investigation.

Conclusions
===========

We demonstrated that fetal myofiber number increased sharply in a pulsed-wave mode at a particular developmental stage and was not augmented evenly across developmental stages in large mammal. The two surges in myofiber hyperplasia occurred at 85 and 120 d in Texel sheep, whereas a single surge appeared at 100 d in Ujumqin sheep during the second half of gestation. A myostatin mutation changed the gene expression profile in prenatal skeletal muscle, particularly disrupting some pivotal signaling pathways governing muscle development and function at some developmental stages, which explains much of the variation in myofiber phenotypes between Texel and Ujumqin sheep. Further studies on the crucial DE genes and signaling pathways involved would be helpful for revealing the mystery of muscle development in mammals.

Methods
=======

Animals
-------

All experimental and surgical procedures were approved by the Biological Studies Animal Care and Use Committee, Shanxi Province, Peoples Republic of China. Seventy-eight Ujumqin and 54 Texel ewes were prepared. These purebred female animals involved were selected based on their age (3-5 years old), body weight (50-55 kg), and body size. After these animals were subjected to pre-feeding for 45 days, estrus was synchronized in all ewes using an implanted controlled internal drug release device (Pharmacia & Upjohn Pty Limited, Parramatta City, NSW, Australia) and intramuscular injections of pregnant mare serum gonadotropin (Ningbo Renjian Pharmaceutical Co., Ltd, Zhejiang, China), according to the manufacturers\' protocol, followed by artificial insemination using the corresponding breed sire\'s sperm. Three pregnant ewes from each breed were subject to caesarean section to collect the fetuses at 70, 85, 100, 120, and 135 d of gestation, and then the 12 different anatomic skeletal muscles from each fetus were dissected and weighed (longissimus dorsi, semitendenosus, semimembranosus, gluteus medius, femoral quadriceps, gastrocnemius, serratus ventralis thoracis muscle, biceps femoris, adductor, supraspinatus, infraspinatus, and triceps brachii). Two samples were taken from each muscle at standardized anatomical sites. The first sample (3 g) was dissected and rapidly frozen whole in isopentane chilled over liquid nitrogen for histological examination. The second sample (5 g) was snap-frozen in liquid nitrogen for gene expression analysis.

Histology analysis
------------------

To examine the development of skeletal muscle in both sheep breeds, we measured the number and the diameter of the longissimus dorsi muscle fiber in Ujumqin and Texel sheep during five development stages using hematoxylin and eosin staining. Serial cross sections of 10 μm thickness were cut at -20°C using a cryostat. Photomicrographs of five to eight randomly selected areas were used to estimate the the diameter and the total number of myofibers in the cross sections of muscle examined. Muscle fiber measurements were conducted using DT2000 (V2.0) image analysis software (Nanjing East-image Ltd., Nanjing, China).

The primary IFS antibodies were rabbit-laminin antibody (Sigma, St. Louis, MO, USA) and mouse monoclonal anti-pax7 (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA). The corresponding secondary antibodies were anti-mouse immunoglobulin (ALEXA488) and anti-rabbit immunoglobulin (ALEXA594) (Invitrogen, Carlsbad, CA, USA). Staining was performed according to the manufacturer\'s instructions. The IFS slides were analyzed using a system of epi-fluorescence microscopes (TE2000U; Nikon, Tokyo, Japan). The satellite cell (SC) nuclei were stained green and the basal lamina, red. Images were subsequently analyzed using Image Pro Plus (v5.1) image analysis software (Media Cybernetics, Inc., Bethesda, MD, USA). The numbers of SCs and myofibers in each section were counted, and the SC concentration within a given area of view was also calculated for each slide.

Data between the two breeds were analyzed using the *t*-test procedure in SPSS 13.0 (SPSS, Inc., Chicago, IL, USA). A p-value of \< 0.05 was considered statistically significant.

Microarray experiment
---------------------

We made five independent comparisons at the same development stages in both breeds using a *t*-test and detected 207, 115, 90, 151, and 72 DE probes with a greater than twofold change at 70, 85, 100, 120, and 135 d of gestation, respectively. The new specialized and standardized transcriptome-wide sheep microarray (Agilent Technologies) contained 15,008 sheep probes sourced from RefSeq and UniGene. The oligo microarray was 15 K in size. The longissimus dorsi muscles from ovine fetuses were investigated for gene expression. The microarray of each development stage for each breed contained three biological replicates (n = 3) except the T100 team (n = 4). Thus, 31 hybridizations in total were performed. Data were deposited in the NCBI database (GSE23563).

Total RNA was extracted from the frozen longissimus dorsi muscles using an RNeasy Mini Kit with DNase treatment (Qiagen, Valencia, CA, USA) according to the manufacturer\'s protocol. The total RNA from each individual was labeled with Cy3 fluorescence. The generated targets were mixed and subjected to hybridization with the Sheep Gene Expression Microarray (Agilent Technologies), according to the manufacturer\'s protocol.

Scanning of the microarrays was performed using a DNA microarray scanner (Agilent Technologies). The scanning parameters were a 5 μm scan resolution, PMT with 100%, and 10% once, respectively. All probe sets whose signals were reported as \"absent\" during the flag call in all 31 arrays were filtered out, and those from probe sets called \"present\" on at least one chip were used for further analysis. Scanner output image files were normalized and filtered using Feature Extraction Software v10.5 (Agilent Technologies).

Statistical analysis of the microarray data
-------------------------------------------

The raw signal intensity data were normalized using the quantile method, and the data were transformed to a base-2 logarithm for further statistical analysis. To explore the difference in gene expression between breeds at each developmental stage, we conducted a comparative analysis with the unpaired unequal variance *t*-test (Welch\'s *t*-test) method in GeneSpring10.0 (Agilent Technologies). Five *t*-test contrasts were performed independently, based on the premise that no relationships existed between the data at different time points. The thresholds for significance were p \< 0.05 and a fold change of twofold or more with FDR \< 0.4.

Gene ontology and functional annotation analysis
------------------------------------------------

Only 1508 of the 15,008 probe set were definitive in the Agilent Sheep Gene Expression Microarray. To further clarify the function of the DE genes in this study, we conducted a BLASTN search for highly homologous human sequences (search setting: query coverage not less than 50%, E value less than 1.00E-100). DAVID Bioinformatics Resources (<http://david.abcc.ncifcrf.gov>) \[[@B93],[@B94]\] and IPA (<http://www.ingenuity.com>) \[[@B95]\] were both used for further functional analysis to identify which molecular events or cascades were involved during skeletal muscle development. Significance was expressed as a p-value, which was calculated using the EASE score (p-values \< 0.05 were considered significant).

Quantitative real-time PCR analysis
-----------------------------------

Total RNA was used to make cDNA using the PrimeScript^®^1st Strand cDNA Synthesis Kit (Takara Bio, Shiga, Japan). q-Real-time PCR was performed on an ABI 7500 instrument (Applied Biosystems, Foster City, CA, USA) using the Fast EvaGreen^®^Master Mix (Biotium, Hayward, CA, USA). Thermal cycling consisted of an initial step at 95°C for 10 min followed by 40 cycles at 95°C for 30 s and 62°C for 30 s. Fifteen DE genes identified in the microarray experiment were selected for validation by q-real-time PCR; *RpLP0*was chosen as the reference gene for normalization of all data because it was expressed more stably \[[@B26]-[@B29]\]. Each q-real-time PCR reaction (in 20 μl) contained 10 μl of Fast EvaGreen^®^Master Mix, 0.5 μl of each primer, 2 μl of normalized template cDNA, and 7 μl water. The q-real-time PCR measurements were performed in triplicate on each cDNA sample (n = 31), and gene expression was quantified relative to *RpLP0*expression using the 2-ΔΔCt method. Gene expression ratios were normalized to the *RpLP0*gene in the same sample.
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###### Additional file 1

**Quality control and validity of the gene expression microarray**. This file contains the analytic settings using GeneSpring10.0 (Agilent) and the detectable rate of Agilent Sheep Gene Expression Microarray.
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Click here for file

###### Additional file 2

**Differentially expressed (DE) genes in skeletal muscle between Texel and Ujumqin sheep at 70 d**. For Additional files 2-6, the *t*-test was employed to identify the DE genes between Texel and Ujumqin sheep at each developmental stage using GeneSpring 10.0 (Agilent). Only those genes with p ≤ 0.05(p-value in Colum B) and an absolute twofold change or more(absolute FoldChange in Colum C) were considered DE genes for further analysis. In the \"regulation\" column, \"up\" or \"down\" indicates that the genes were upregulated or downregulated in Texel fetal sheep, respectively, compared with those in Ujumqin fetal sheep.
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###### Additional file 3

**Differentially expressed (DE) genes in skeletal muscle between Texel and Ujumqin sheep at 85 d**.
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###### Additional file 4

**Differentially expressed (DE) genes in skeletal muscle between Texel and Ujumqin sheep at 100 d**.
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###### Additional file 5

**Differentially expressed (DE) genes in skeletal muscle between Texel and Ujumqin sheep at 120 d**.
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###### Additional file 6

**Differentially expressed (DE) genes in skeletal muscle between Texel and Ujumqin sheep at 135 d**.

###### 
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